3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
269
Neoplasms
148
Breast Neoplasms
146
Colorectal Neoplasms
128
Neoplasm Metastasis
96
Prostatic Neoplasms
95
Multiple Myeloma
94
Ovarian Neoplasms
93
Lung Neoplasms
88
Squamous Cell Carcinoma of Head and Neck
64
Pancreatic Neoplasms
64
Recurrence
62
Endometrial Neoplasms
58
Small Cell Lung Carcinoma
52
Melanoma
52
Stomach Neoplasms
50
Leukemia, Lymphocytic, Chronic, B-Cell
48
Carcinoma, Renal Cell
47
Leukemia, Myeloid, Acute
46
Lymphoma, Non-Hodgkin
41
Advanced Solid Tumors
40
Urinary Bladder Neoplasms
38
Triple Negative Breast Neoplasms
38
Parkinson Disease 4, Autosomal Dominant Lewy Body
38
Head and Neck Neoplasms
38
Lymphoma, Large B-Cell, Diffuse
36
Carcinoma, Hepatocellular
35
Esophageal Neoplasms
32
Lymphoma, Follicular
30
Colonic Neoplasms
29
Interventions
pembrolizumab
1
enfortumab vedotin
1
Radiation Dose Hypofractionation
1
Mitomycin
1
Gemcitabine
1
Fluorouracil
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Urogenital Diseases
×
30 days
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled